ReutersPfizer stops enrollment in Paxlovid trial in standard-risk populationJun 14, 2022Leroy Leo D'souzaBy Leroy Leo D'souzamore_vert
STATPfizer's Paxlovid study fails to answer key questions over benefit for broader populationsJun 14, 2022Matthew Herper & Jason MastBy Matthew Herper & Jason Mastmore_vert